Xevinapant is under clinical development by Merck and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Xevinapant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Xevinapant overview

AT-406 (Debio-1143) is under development for the treatment of locally advanced squamous cell carcinoma of the head and neck and non-small cell lung cancer (NSCLC), small-cell lung cancer, esophageal cancer, oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer, epithelial ovarian cancer, primary peritoneal cancer, gastric cancer, colorectal cancer, endometrial cancer, cervical cancer, head and neck cancer squamous cell carcinoma, advanced malignancy and pancreatic ductal adenocarcinoma as second line therapy. It is formulated as a capsule and is administered through oral route. The drug candidate acts by targeting IAP repeat-containing protein 2 (CIAP1), IAP repeat-containing protein 3 (CIAP2), IAP repeat-containing protein 7 (livin) and IAP repeat-containing protein 4 ( XIAP). It is a new chemical entity. It was also under development for the treatment of pancreatic cancer, prostate cancer, bladder cancer, relapsed acute myelogenous leukemia (AML), advanced solid tumors, lymphomas, epithelial ovarian cancer and basal-like/claudin-low triple negative breast cancer.

Merck overview

Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

For a complete picture of Xevinapant’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.